Lp-PLA2 and dual antiplatelet agents in intracranial arterial stenosis

Neurology. 2020 Jan 14;94(2):e181-e189. doi: 10.1212/WNL.0000000000008733. Epub 2019 Dec 10.


Objective: To evaluate the interaction effect of lipoprotein-associated phospholipase A2 (Lp-PLA2) activity on the efficacy and safety of dual/single antiplatelet therapy in patients with and without intracranial arterial stenosis (ICAS) by the Clopidogrel in High-Risk Patients with Acute Non-disabling Cerebrovascular Events trial.

Methods: Patients with both MRI analysis and Lp-PLA2 testing results were included in the current subanalysis. The interaction of Lp-PLA2 activity with the effects of dual and single antiplatelet therapy were analyzed through Cox proportional hazards regressions model.

Results: Among the 797 patients, the mean age was 63.1 ± 10.8 years, 518 (65%) were men, 356 (44.7%) had ICAS, and 441 (55.3%) did not. There were significantly more patients with elevated Lp-PLA2 activity in the ICAS group than in the non-ICAS group (43.8% vs 35.4%, p = 0.02). There was significant interaction between Lp-PLA2 activity levels and the 2 antiplatelet therapies for prevention of stroke recurrences and combined vascular events even after adjustment for confounding factors exclusively for patients with ICAS (p = 0.017, 0.017, respectively), but not for those without (p = 0.332, 0.674, respectively). Compared with aspirin alone, dual antiplatelet therapy significantly reduced the risk of stroke recurrences and combined vascular events (adjusted hazard ratio 0.33 [0.12-0.89], p = 0.028; 0.33 [0.12-0.89], p = 0.028, respectively) for patients with ICAS and nonelevated Lp-PLA2 activity.

Conclusions: Presence of both ICAS and nonelevated Lp-PLA2 activity may predict better response to dual antiplatelet therapy in prevention of recurrent strokes and combined vascular events for patients with minor stroke or high-risk TIA.

Clinicaltrialsgov identifier: NCT00979589.

MeSH terms

  • 1-Alkyl-2-acetylglycerophosphocholine Esterase / metabolism*
  • Aged
  • Aspirin / therapeutic use
  • Cerebrovascular Disorders / drug therapy*
  • Cerebrovascular Disorders / metabolism*
  • Clopidogrel / therapeutic use
  • Female
  • Humans
  • Male
  • Middle Aged
  • Platelet Aggregation Inhibitors / therapeutic use*
  • Recurrence
  • Stroke / metabolism
  • Stroke / prevention & control


  • Platelet Aggregation Inhibitors
  • Clopidogrel
  • 1-Alkyl-2-acetylglycerophosphocholine Esterase
  • PLA2G7 protein, human
  • Aspirin

Associated data

  • ClinicalTrials.gov/NCT00979589